UOS Tumori Polmonari - IRCCS AOU San Martino -IST- Istituto Nazionale per la Ricerca sul Cancro
Welcome,         Profile    Billing    Logout  
 11 Trials 
7 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Grossi, Francesco
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Active, not recruiting
3
151
Europe, US, RoW
Pyrotinib, Irene, Docetaxel, Docetaxel injection
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous NSCLC, HER2 Exon 20 Mutation
06/23
10/23
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
CHANCE, NCT03976518: Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies ( Trial)

Completed
2
43
Europe
Atezolizumab
Gruppo Oncologico Italiano di Ricerca Clinica, AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology, Istituto Toscano Tumori, YGHEA, CRO Division of Ecol Studio spa, Iqvia Pty Ltd, AOU S. Orsola Malpighi - Clinical Trial Office, Silvano Chiapparoli Logistica SpA, Roche SpA
Non-Small Cell Lung Cancer
02/24
02/24
THOR, NCT05623319 / 2020-004834-39: Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)

Recruiting
2
60
Europe
Pembrolizumab/Olaparib
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Merck Sharp & Dohme LLC
SCLC,Extensive Stage
10/26
10/26
NCT03917381 / 2018-003402-63: GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Active, not recruiting
1/2
429
Europe, US, RoW
Acasunlimab, GEN1046, DuoBody®-PD-L1x4-1BB, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Genmab, BioNTech SE
Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer
02/26
02/26
Key-Early, NCT06467383: A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced

Recruiting
N/A
600
Europe
MSD Italia S.r.l., YGHEA, CRO Division of Ecol Studio spa
Non-small Cell Lung Cancer, NSCLC, NSCLC, Stage III, NSCLC, Stage I
06/25
06/25
NCT05376891: Met Non Small Cell Cancer Registry (MOMENT)

Recruiting
N/A
700
Europe, Canada, US, RoW
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Cancer
03/27
03/27

Download Options